

Art Unit: 1631

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 07/14/2008 has been entered.

Claims 12-22 are pending.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 12-22 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 12-19, 23, 24, and 26 of copending application Serial No. 08/612,661. The admixtures addressed in the claims of both applications include embodiments in common embodiments which supports this rejection. These embodiments are directed to sterically bulky groups on the nucleobases well beyond the attachment site to the backbone which are clearly embodiments in common between these sets of claims.

This is a provisional obviousness-type double patenting rejection, even though the only rejection due to the earlier indication of allowability of copending 08/612,661; thus presumed to issue first before the instant application.

The above rejection was first made in the Office action of 12/19/2000 and reiterated in the Office actions of 12/16/2003 and 06/10/2004. Applicant then filed Terminal Disclaimer which was accepted on 02/17/2005. Consequently, the double-patenting rejection has been withdrawn at the time of allowance (04/14/2008).

Thereafter, applicant contacted SPE Marjorie Moran on June 9, 2008 (see Applicant's summary of interview with examiner of 07/14/2008) and informed that an error in the previously submitted terminal disclaimer to copending application No. 08/612,661 was made. Applicant informed The previously submitted terminal disclaimer inadvertently listed Isis Pharmaceuticals as the owner, whereas the owner should have been listed as Peter Nielsen. During the interview, it was decided that Applicants could file a replacement terminal disclaimer listing the correct owner.

Art Unit: 1631

Therefore, the double-patenting rejection is reiterated as previously applied.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Borin whose telephone number is (571) 272-0713. The examiner can normally be reached on 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marjorie Moran can be reached on (571) 272-0720. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael Borin, Ph.D./  
Primary Examiner, Art Unit 1631